Company* |
University/ |
Type Of Agreement | Product Area |
Details (Date) |
| ||||
| ||||
Accelrys |
Boston University |
Distribution agreement |
Two new software methods for studying protein-protein docking |
Accelrys will distribute the ZDOCK and RDOCK algorithms under undisclosed terms (6/15) |
| ||||
Aclara |
Tokyo |
Collaboration |
They will evaluate |
Aclara's eTag technology will be used to validate candidate biomarkers; Aclara will fund the |
| ||||
AEterna Zentaris |
German |
License |
Deal covering disorazoles, a class of natural products with potential |
Zentaris GmbH gets an exclusive global license in exchange for an up-front payment, annual |
| ||||
Agilent |
Translational |
Collaboration |
Oligonucleotide microarray technology called comparative genomic |
TGen gets early access to the technology, which will be applied to identifying and locating genetic alterations that contribute to cancer (6/8) |
| ||||
AnalytiCon |
Memorial Sloan-Kettering Cancer Center |
Collaboration |
Deal to combine technologies to discover and develop drugs for cancer |
They will use AnalytiCon's natural products and chemistries with the center's biology and screening technologies; terms were not disclosed (7/23) |
| ||||
Athersys Inc.* |
National Heart, Lung and Blood Institute |
Cooperative Research and Development Agreement |
To jointly develop and apply stem cell technology for treating cardiovascular disease |
They will use Athersys' MAPC technology that is based on an adult-derived stem cell, as well as its genomics technologies, in the effort (5/20) |
| ||||
Australian |
Memorial Sloan-Kettering Cancer Center |
Agreement |
The center will use the GPI-0100 adjuvant in a series of clinical trials in cancer indications |
The deal was made with Galenica Pharamceutcials Inc.; ACT's acquisition of Galenica was finalized the next day (6/22); second deal involves the center studying PI-0100 vaccinations in lymphomas and leukemias (7/1) |
| ||||
Bionomics Ltd. |
Louisiana State |
Collaboration |
The school's gene-delivery technology will be used to deliver gene expression-silencing molecules to solid tumors |
Bionomics will have commercialization rights on resulting cancer treatments (7/30) |
| ||||
Bionomics |
University of Wisconsin Medical School |
Collaboration |
The deal centers on an animal model of epilepsy |
Bionomics will provide UWMS the model and get access to resulting intellectual property (7/7) |
| ||||
Biosystemix |
S2K |
Partnership |
To develop computational models for disease susceptibility, progression and response |
Biosystemix will work with S2K, a consortium of genomics researchers funded by Genome Canada and Genome Quebec (6/14) |
| ||||
BioTrove Inc.* |
Stanford University |
License |
For patent applications |
BioTrove licensed use of a through-hole-structured micro-array to perform PCR; terms were not disclosed (7/15) |
| ||||
Cellectis SA* |
Four research |
License |
The centers got rights to technology for replacing or inserting genes by homologous recombination |
The centers gained nonexclusive sublicenses to the technology under undisclosed terms; the deal was brokered by Ascenion GmbH (5/26) |
| ||||
Clinomics |
H. Lee Moffitt Cancer Center and Research Institute |
Collaboration |
To develop new technologies for use in cancer research |
The initial work will focus on use of Clinomics' Tissue Micro Array technologies to improve the diagnosis and classification of primary tumors (7/13) |
| ||||
CytRx |
University of Massachusetts Medical School |
Expanded collaboration |
CytRx has an option to license UMMS discoveries over three years in RNAi, diabetes, obesity, neuro-degenerative diseases and cytomegalovirus |
CytRx will make certain cash payments over two years in consideration of invention disclosures, then could make payments to negotiate exclusive licenses to the discoveries (7/19) |
| ||||
CytRx |
Imperial College London |
License agreement |
The college's drug-screening method using a nuclear hormone co-repressor that regulates fat accumulation |
CytRx got an exclusive license to the technology in exchange for a license fee and potential milestone payments and royalties on resulting sales (5/20) |
| ||||
DOR BioPharma |
U.S. Army's Medical Research Institute of Infectious Diseases |
Cooperative Research and Development Agreement |
To advance development of DOR's mucosally delivered vaccine for botulinum toxin |
USAMRIID will supply antigens and reagents, while DOR and the university will develop and test formulations (6/16) |
| ||||
Entelos Inc.* |
American Diabetes Association |
Collaboration |
To develop an in silico research platform based on a non-obese diabetic mouse |
The platform initially will be used by Entelos and certain research laboratories to address scientific questions related to Type I diabetes (6/9) |
| ||||
Genentech |
Cancer Research Technology (UK) |
License agreement |
Genentech gets exclusive worldwide rights to patents covering an oncology target |
Genentech plans to evaluate protein therapeutics against the target; terms were not disclosed (7/20) |
| ||||
Generex |
Saint Savas Cancer Center (Greece) |
Collaboration |
To use modified peptide antigens to stimulate cancer patients' immune cells |
The work, involving Generex subsidiary Antigen Express, is designed to lead to trials of a vaccine in patients with ovarian cancer (6/1) |
| ||||
GenPhar Inc.* |
U.S. Army |
Amended contract |
To develop and test multivalent vaccines for Marburg and Ebola viruses |
The funding increased from $1M to $6M over the next two years; GenPhar intends to contract with the Medical University of South Carolina to perform some services (7/30) |
| ||||
Genzyme |
Project HOPE |
Partnership extension |
To provide enzyme-replacement therapy to Gaucher's patients around the world |
Under the Gaucher Initiative program, Genzyme donates Ceredase and funding while Project HOPE distributes the drug and provides other services (7/15) |
| ||||
HepaLife |
USDA's Agricultural Research Service |
Cooperative Research and Development Agreement |
To optimize hepatic functionality of the PICM 19 cell line for use on an artificial liver device |
Work under the deal's three-year expansion also will involve testing liver cell-specific toxicoloy and metabolism based on the cell line (6/1) |
| ||||
Hybrigenics |
Shanghai Institute of Materia Medica (China) |
Collaboration |
To use traditional Chinese medicines to develop therapeutics |
Hybrigenics will supply targets and a screening assay and SIMM will provide plant extracts in a cost-sharing arrangement (5/17)** |
| ||||
ImmuneRegen |
University of Arizona College of Medicine |
Grant |
To test the efficacy of direct muscle injection of Homspera for gamma radiation |
ImmuneRegen is funding testing at the university (6/16) |
| ||||
Immunicon |
Twente University (the Netherlands) |
Development and license agreement |
Amended deal to develop an instrument to monitor HIV |
The test would be an additional application to Immunicon's Cell-Tracks EasyCount system, which the parties developed (6/17) |
| ||||
Interleukin Genetics |
Tufts University |
License agreement |
Products based on variations in the perilipin gene, which affects body weight |
IGI gests exclusive rights to develop and sell tests based on the gene, and may develop nutritional products; terms were not disclosed (6/28) |
| ||||
Interleukin Genetics |
Vanderbilt University Medical Center |
Collaboration |
To evaluate the effectiveness of certain anti-inflammatory agents on endometriosis |
IGI has expertise in the genetics of inflammation and Vanderbilt has knowledge of endometriosis disease mechanisms (6/14) |
| ||||
IQ Corp.* |
Centers for Disease Control and Prevention |
Agreement |
The CDC will test four of IQ's anthrax products |
The CDC and Department of Health and Human Services will evaluate toxin- neutralizing capacities of the antibodies (6/23) |
| ||||
IQ Corp.* |
U.S. Naval Medical Research Center |
Cooperative Research and Development Agreement |
To develop fully human monoclonal antibodies against biological threat agents |
The focus is on development of IQ's Anthraxumab product against anthrax toxin, and on other biological threats (6/2) |
| ||||
Juvaris |
Colorado State University |
License agreement |
To develop therapeutic vaccines using receptor ligands complexed to lipids |
CSU gets licensing fees and would get royalties on resulting sales; the mechanism is to activate an array of Toll- like receptors (5/25) |
| ||||
KaloBios |
Ludwig Institute for Cancer Research (Australia branch) |
License agreement |
Antibody drug candidate for the treatment of autoimmune diseases |
The initial focus is rheumatoid arthritis, and human trials are planned for 2H:05; terms of the deal were not disclosed (7/22) |
| ||||
KaloBios |
Medical College of Wisconsin and the University of California at San Francisco |
License agreement |
Preclinical therapeutic antibody and related intellectual property directed at Pseudomonas aeruginosa |
Terms were not disclosed; the antibody is deisgned to neutralize the action of the PcrV protein of the Type III secretion system (6/2) |
| ||||
Kalypsys Inc.* |
National Institutes of Health |
Access agreement |
Kalypsys' platform of lead-discovery solutions |
The deal is worth up to $30M to Kalypsys; its technologies will be used by the newly created NIH Chemical Genomics Center (6/9) |
| ||||
KuDOS |
University of Cambridge and Cancer Research Technology Ltd. (both in the UK) |
Agreements |
Research on DNA repair developed at the university |
The deals enable KuDOS' continued access to the research, on which it is developing small moleclues for cancer applications; terms were not disclosed (6/28) |
| ||||
Large Scale |
University of Louisville |
Collaboration |
To develop therapeutics to prevent and treat diseases caused by human papillomaviruses |
They will jointly fund the program that will draw on each party's areas of expertise in the field (6/28) |
| ||||
LigoCyte |
Baylor College of Medicine |
License agreement |
LigoCyte exercised an option to technologies related to norovirus vaccines and drugs |
Terms were not disclosed; Baylor has an oral Norwalk virus vaccine candiate in Phase I trials (5/25) |
| ||||
Lynx |
National Institute of Mental Health |
Service agreement |
To use Lynx's MPSS genomic- analysis technology to study gene expression in the brain |
Terms were not disclosed; they will focus on the dorsolateral prefrontal cortex region of the brain that has been implicated in schizophrenia (5/21) |
| ||||
MediGene |
University of Chicago |
License agreement |
Targeting technology that uses herpes simplex virus; for cancer applications |
MediGene licensed a specific method of targeting HSV to tumor cells, which it already is using in clinical trials; terms were not disclosed (6/28) |
| ||||
Meridian |
Cincinnati Children's Research Foundation |
License agreement |
Meridian got rights to technology related to the diagnosis of noroviruses |
Terms were not disclosed; noro-viruses cause acute gastroenteritis (5/26) |
| ||||
MicroIslet Inc. (AMEX:MII) |
University of California at Davis |
Collaboration |
Deal on islet-cell transplantation therapies for insulin-dependent diabetes |
Tests on nonhuman primates will use MicroIslet's technology in pig islets; it will fund work at the university and have a right to license any discoveries (6/23) |
| ||||
Millennium |
Harvard University |
Research agreement |
Deal on a family of proteasome inhibitors and a related chemical- synthesis process |
Millennium gained certain rights to use the process in exchange for milestone fees and royalties on any resulting sales (6/2) |
| ||||
Miraculins |
Edmonton Prostate and Urological Research Centre (Canada) |
Collaboration |
Miraculins will get clinical samples from prostate cancer patients matched with samples from control patients |
Miraculins will apply its BEST platform to the discovery of prostate cancer markers; terms were not disclosed (7/28) |
Nastech |
Cedars-Sinai Medical Center |
License agreement |
Nastech got exclusive rights to peptide YY, a hormone associated with modulation of appetite circuits |
CSMC will receive license fees, milestone payments and royalties on any resulting sales; the technology is used in Nastech's investigational PYY3-36 nasal spray for obesity (5/24) |
| ||||
Nucleonics Inc.* |
University of California |
License agreement |
A class of promoters for transcribing expressed interfering RNAs |
Nucleonics got exclusive worldwide and sublicense rights to the technology on eukaryotic RNA Pol III promoters in the field; terms were not disclosed (6/3) |
| ||||
PamGene |
University of Nottingham (UK) |
License agreement |
PamGene's 3-D flow-through microarray platform |
The university licensed the technology to develop multiplex amplifiable probe hybridization on the PamGene platform (7/12) |
Peregrine Pharmaceuticals |
University of Texas M.D. Anderson Cancer Center |
License agreement |
Worldwide license covering antiphosphatidylserine antibodies |
M.D. Anderson will get an up-front fee and potential milestone and royalty payments; the technology relates to inducing auto-immunity in treating cancer (7/6) |
| ||||
Phytomedical Technologies |
New York University |
Exclusive worldwide rights agreement |
For pharmacologically active elements of a muira puama plant extract and ion channel modulators from natural sources |
Phytomedical will pay the school a royalty on net sales of all licensed products, and granted it an option to acquire Phytomedical stock; the first compound, BDC 03, has shown its ability in animal studies to reduce body-fat percentage, increase lean muscle mass and lower cholesterol (8/5) |
| ||||
Piramed |
The Institute of Cancer Research at Royal Cancer Hospital (UK) |
Research collaboration |
To develop cancer drugs targeting the P13 kinase-transduction enzyme |
They will conduct preclinical pharmacokinetic and efficacy studies of two series of Piramed compounds (5/20) |
| ||||
Plantacor Inc.* |
University of Texas M.D. Anderson Cancer Center |
License agreement |
Plantacor exclusively licensed rights to three preclinical cancer compounds |
M.D. Anderson gained an equity position in Plantacor in exchange for rights to liposomal formulations of Curcumin and Emodin and to Calagualine (7/27) |
| ||||
PolyNovo |
Imperial College London |
Collaboration |
Deal to further develop PolyNovo's polymer technology for bone repair |
The polymers can be formulated as an injectable gel that cures in situ or on demand, and are designed to promote tissue growth and the rate of degradation (7/19) |
| ||||
Power3 Medical Products Inc. (OTC BB: PWRM) |
Baylor College of Medicine |
License agreement |
For serum proteomics methods and biomarkers for diagnosing neuro-degenerative diseases |
Power3 paid a licensing fee and would make milestone payments as products develop, as well as royalties on resulting sales (7/20) |
| ||||
QLT Inc. (Canada; QLTI) |
National Eye Institute |
Cooperative Research and Development Agreement |
To study preservative-free triamcinolone acetonide as an adjunct to Visudyne in wet age-related macular degeneration |
QLT will fund a 300-patient trial of the combination and gains the option to an exclusive license for certain rights to PFTA in combination with Visudyne (6/2) |
| ||||
Scancell Ltd.* (UK) |
Cancer Research Technology Ltd. (UK) |
License agreement |
Scancell got rights to vaccines against the protein targets Tie-2 and CD55 |
The targets are implicated in solid tumors; the license is exclusive and worldwide (5/25) |
| ||||
Sequenom Inc. (SQNM) |
National Human Genome Research Institute |
Cooperative Research and Development Agreement |
Sequenom will perform allele-specific gene expression of genes conferring susceptibility to Type II diabetes |
The three-year deal builds on previous work between the parties, and will employ Sequenom's MassARRAY technology; terms were not disclosed (7/22) |
| ||||
Targeted Genetics Corp. (TGEN) |
National Institutes of Health |
License agreement |
Patents that cover inverted terminal repeat sequences as a promoter when using adeno-associated viral vectors |
Targeted Genetics got an exclusive worldwide license to the technology for any indication; terms were not disclosed (6/4) |
| ||||
Targeted Molecular Diagnostics LLC* |
University of Texas M.D. Anderson Cancer Center |
Collaboration |
To study the utility of cyclin E in predicting outcomes in liver surgery due to metastases from colon cancer |
They already have worked in the area of cell-cycle regulators in breast cancer; TMD intends to develop biologic markers (6/21) |
| ||||
TopoTarget A/S* (Denmark) |
National Cancer Institute |
Cooperative Research and Development Agreement |
To develop a series of inhibitors of histone deacetylase |
Research will focus on identifying drugs to use with TopoTargets' HDAC inhibitor PXD101, which is in Phase I trials (5/19)** |
| ||||
Trillium Therapeutics Inc.* (Canada) |
St. Justine Hospital and the University of Montreal (both in Canada) |
License agreement |
A series of pro-inflammatory cytokine receptor antagonists |
Terms of the deal were not disclosed; Trillium will fund work on the program at the institutions (6/2) |
| ||||
Tripos Inc. (TRPS) |
European Molecular Biology Laboratory and the German Cancer Research Centre (both in Germany) |
Services agreement |
Tripos will apply its chemistry technologies to identify molecular leads at screening facilities in Germany |
The German centers brought in the expertise of Tripos in chemistry and small molecules to complement their strength in biology (7/20) |
| ||||
Vertex Pharmaceuticals Inc. (VRTX) |
Cystic Fibrosis Foundation |
Collaboration expansion |
For continued development of Vertex's efforts in CF drug discovery |
Vertex will receive $21M through 2005 under an expanded collaboration; Vertex retains all rights to its products (5/24) |
| ||||
| ||||
Notes: | ||||
This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers. | ||||
* Denotes privately held company. | ||||
** Item occurred before the time frame of this chart but was not included in the previous chart. | ||||
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; VSE = Vancouver Stock Exchange. |